Iris Holm: Lila, I want to start with a sentence and see if it survives — a drug just got approved that near-quadrupled survival time for patients with no other options, and the developer's stock cratered the same day.
Lila Soto: Oh that's — I mean, that sounds like it shouldn't be possible.
Iris Holm: It's not a paradox. It's Celcuity, July 14th, 2026. FDA approves Revtorpyk — gedatolisib — for HR+/HER2-negative breast cancer. CELC falls nearly twenty percent.
Lila Soto: So what's the episode — what are we actually trying to untangle?
Iris Holm: Whether Wall Street's read was rational or whether they're just bad at valuing drugs that serve populations medicine ignored for years. Because PIK3CA wild-type patients — sixty percent of HR+/HER2-negative cases — had zero precision pathway. Zero. Before this approval.
Lila Soto: Sixty percent. That's not a niche patient population, that's kind of the majority.
Iris Holm: Right. And the VIKTORIA-1 trial — the Phase III that got this approved — showed 9.3 months median progression-free survival for the triplet versus two months on fulvestrant alone. That number should be the whole story. The fact that it isn't — that's what we're here to explain.
Lila Soto: Yeah — and I think what's underneath that gap is more interesting than the stock price itself.
Iris Holm: But that gap — the interesting part — it's not about the science. It's about Celcuity specifically.
Lila Soto: Meaning — what, their size? Because they're not a Pfizer launching this.
Iris Holm: Revtorpyk is their first FDA-approved product. Ever. Celcuity has never launched a commercial drug before. That's the signal investors were reading.
Lila Soto: Okay, and that matters because — I mean, first launches are operationally hard even for companies that have done it before, right? But there's also the timing thing. They disclosed a delayed commercial launch, only expected in late Q3 2026. So you get FDA approval in July and then... you wait?
Iris Holm: That delay is the prescribing information surprise. Analysts at Jefferies — who had called the triplet 'practice-changing' — apparently weren't fully pricing in what the label constraints would actually look like in the real world.
Lila Soto: And that actually stopped me when I was thinking about this. Revtorpyk is IV. Alpelisib — Piqray — is a pill. You take it at home. So think about a woman who just got her PIK3CA wild-type result back, yeah there's finally a drug for her — but it means infusions. Scheduling, a clinic, someone to drive her. That's not the same access calculation at all.
Iris Holm: IV versus oral is a commercial cliff. Oral agents scale. IV doesn't — not in a narrow-indication launch with maybe 40,000 initially addressable patients in the U.S.
Lila Soto: So the stock drop wasn't panic. It was — yeah, it was structural. First-time launcher, IV drug, delayed rollout, narrow population. That's not irrational skepticism. That's math.
Iris Holm: But the math only lands right if you understand why wild-type patients had nothing in the first place. That's the part that actually breaks your brain.
Lila Soto: Yeah — and I want to try to say this plainly because I think the mechanism is the whole story. Like, imagine a lock with four tumblers. Alpelisib — Piqray — only turns one of them. That works great if the mutation is sitting right there in that specific tumbler.
Iris Holm: And PIK3CA wild-type means that tumbler isn't the problem.
Lila Soto: Exactly — so the key doesn't even fit. But gedatolisib turns all four tumblers at once, which is why it can reach disease where there's no PIK3CA mutation driving it at all. That's the one sentence. The mechanism opens the door Piqray can't even reach.
Iris Holm: Right. And the scale of who's on the other side of that door — HR+/HER2-negative is roughly seventy percent of all breast cancers. Sixty percent of those patients are wild-type. That's not a corner case.
Lila Soto: Before July 14th, 2026, their option was fulvestrant. Endocrine therapy alone. No precision pathway, no targeted mechanism — just the standard hormonal play and hope it holds.
Iris Holm: That's the unmet need. Not manufactured. Not a marketing framing. Actually real.
Lila Soto: And — mm — the FDA approved both a doublet with fulvestrant and a triplet with palbociclib and fulvestrant, so prescribers actually have real flexibility on paper. But there's a split coming that I think makes this worse, and we need to get to it.
Iris Holm: The regulatory split. Wild-type approved, PIK3CA-mutated still pending a separate decision. One approval, two populations, one commercial launch. That's not precision — that's fragmentation dressed as precision.
Lila Soto: And that fragmentation — I mean, that's not just a regulatory footnote. That's the commercial ceiling sitting right there in the approval letter.
Iris Holm: It is. The mutated cohort already has alpelisib. So Revtorpyk's path there isn't open water — it's a head-to-head against Piqray, still pending. Until that decision lands, the addressable market is structurally capped.
Lila Soto: Okay but — before we accept that framing — is 9.3 months versus 2 months enough to win the mutated market anyway? Like, does the efficacy carry?
Iris Holm: That's the right question. And actually — no, wait — it's two separate questions. The wild-type number is 9.3 versus 2. The doublet alone is 7.4 versus 2. Both against fulvestrant monotherapy. Jefferies called the triplet practice-changing specifically because it roughly doubled PFS against Piqray comparators. That's not a soft word from a bank.
Lila Soto: Doubled against Piqray comparators — that's the specific number that makes 'practice-changing' not just analyst hype.
Iris Holm: Right. So the clinical case holds. The VIKTORIA-1 data is the anchor — it doesn't bend under scrutiny. What bends is the commercial translation. The split approval means Celcuity launches into one cohort, not two.
Lila Soto: So the calibrated version — what actually survives once you strip the noise — is something like: the drug works, the trial data is real, the flexibility of having both the doublet and triplet regimens approved is genuinely useful for prescribers. But the commercial story is... kind of half-built until the PIK3CA-mutated decision comes through.
Iris Holm: That's it. Frankly — that's the defensible claim. VIKTORIA-1 is practice-changing for wild-type patients. Full stop. The precision oncology logic that got it approved is also the exact mechanism that fragments the launch. Those two things are true simultaneously.
Lila Soto: The science opened a door that the regulatory structure is only letting half the patients walk through. For now.
Iris Holm: Fine. The stock market wasn't wrong. It was just measuring a different kind of success. CELC dropped twenty percent on the day Celcuity proved the science works — and both of those things are true.
Lila Soto: Yeah, and that's — I mean, that's actually the uncomfortable place to land, isn't it. Revtorpyk is proof that you can build a drug targeted at a population nobody had named yet, run VIKTORIA-1, near-quadruple survival, get the FDA to say yes on July 14th, and still face a completely open question about whether a first-time launcher with an IV drug and a split approval can actually get it into patients' arms.
Iris Holm: That's not a failure of precision oncology. That's precision oncology's next unsolved problem.
Lila Soto: Mm. Yeah. I think that's where I actually am on this.
Iris Holm: Good place to stop.
Lila Soto: Thanks for walking me through the hard parts.
